CBD and Chronic Pain – What Does Science Say, What Does Marketing Say? 2026 Guide

Chronic pain affects approximately 20% of the adult population worldwide, according to estimates from the IASP (International Association for the Study of Pain). In Poland, as indicated by an analysis published in the journal "Ból" (Polish Pain Society, 2022), this issue concerns 27% of adults, which is over 8 million people. This is a large group seeking relief beyond traditional opioids and NSAIDs.

Advertisements for CBD oils promise almost miraculous effects. Meanwhile, a groundbreaking report National Academies of Sciences, Engineering, and Medicine A 2017 study found that there is "conclusive or strong evidence" for cannabinoids only in certain types of chronic pain, mainly neuropathic and cancer-related pain. CBD alone as a monotherapy has a significantly more modest evidence base.

This article separates science from marketing promises. We will show what the Cochrane reviews (2018), BMJ (2021), and the systematic review by McDonagh et al. (2024) really show. We will discuss the mechanisms of action of CBD on CB2 receptors, TRPV1, 5-HT1A, clinical doses of 25-50 mg twice daily, and the importance of formulation. No fluff, no "miraculous" promises.

KEY INFORMATION
– For neuropathic pain, the evidence is moderate: pain reduction of about 30% on the NRS scale in combined analyses of CBD and CBD/THC (BMJ, 2021).
– In fibromyalgia, the data is mixed; in nonspecific low back pain, insufficient (McDonagh et al., 2024).
– The FDA has approved pure CBD (Epidiolex) only for treatment-resistant epilepsy, not for pain (FDA, 2018).
– Doses tested in RCTs are usually 25-50 mg twice daily, not 5-15 mg as supplements.
– Formulation matters: broad spectrum extracts provide a stronger effect than isolates (Gallily et al., Pharmacology & Pharmacy, 2015).
– Marketing oversells: "CBD cures pain" is an exaggeration. Realistically, CBD is an adjunctive tool with a moderate effect in selected pain syndromes.

What is chronic pain and who does it affect?

Chronic pain is defined by IASP as pain that persists or recurs for more than 3 months, regardless of the original cause. The ICD-11 classification distinguishes seven categories: primary, cancer-related, postoperative, neuropathic, headache, visceral, and musculoskeletal. Each has a different mechanism and response to therapies.

The scale of the problem is significant. In Europe, 19% of adults live with moderate to severe pain (Breivik et al., European Journal of Pain, 2006). In the USA, chronic pain affects 20.9% of adults according to the CDC from 2021, and 7.8% experience "high-impact chronic pain" significantly limiting their functioning. The Polish population has similar rates according to NIZP-PZH studies.

The impact on daily life is serious. Insomnia affects 50-80% of patients with chronic pain, depression 30-50%, anxiety disorders about 35% (Polish Society for the Study of Pain, 2022). These comorbid issues exacerbate the perception of pain, creating a vicious cycle. Therefore, effective therapy must address not only pain but also sleep, anxiety, and mood.

Why are classical medications insufficient?

Opioids work strongly but carry the risk of addiction, tolerance, and overdose. The opioid crisis in the USA claimed over 80,000 lives in 2023 (CDC). NSAIDs, such as ibuprofen or naproxen, have cardiovascular and gastrointestinal limitations. Paracetamol in high doses is hepatotoxic.

Gabapentinoids (gabapentin, pregabalin) and tricyclic antidepressants (amitriptyline, duloxetine) are standard in neuropathic pain, but patient tolerance can be low. Drowsiness, dizziness, weight gain, and the risk of misuse limit long-term use. Hence, there is interest in alternatives, including cannabinoids.

What does it mean to "treat pain" in 2026?

Modern pain medicine has shifted from the "pain elimination" model to a biopsychosocial model. The goal is not zero pain, but improved functioning, sleep, and quality of life. In this context, CBD makes sense as part of a multimodal therapy if the patient is realistically informed about the expected effect. It is not a magic pill, but a supportive tool.

How CBD Works on Pain – Molecular Mechanisms

CBD does not strongly bind to the classical CB1 and CB2 receptors of the endocannabinoid system. Instead, it modulates pain through at least four independent pathways: activation of the 5-HT1A receptor, TRPV1 channel, inhibition of FAAH (the enzyme that breaks down anandamide), and indirect influence on CB2 in immune cells (Frontiers in Pharmacology, 2018).

First pathway: 5-HT1A receptor. CBD is a partial agonist of this receptor, which explains its anxiolytic effect and influence on descending pain control. The serotonin system modulates pain signals sent from the brain to the spinal cord, inhibiting their transmission. This is the same mechanism used by duloxetine in fibromyalgia.

Second pathway: TRPV1 channel, or vanilloid receptor. This is the same channel activated by capsaicin from chili peppers. CBD desensitizes TRPV1, reducing the excitability of pain neurons in the skin and deep tissues. The effect is significant in neuropathy and localized pain. This partially explains the effect of topical CBD preparations on joints and muscles.

The third pathway: inhibiting FAAH (fatty acid amide hydrolase). FAAH breaks down anandamide, an endogenous cannabinoid with analgesic effects. By inhibiting FAAH, CBD indirectly increases the level of anandamide and prolongs the action of the body's own endocannabinoid system. This is a "background enhancement," not direct receptor stimulation.

The role of the CB2 receptor in inflammatory states

The CB2 receptor is mainly found on immune system cells: macrophages, T lymphocytes, and microglia in the brain. CBD is not a classical agonist of CB2 but modulates its activity allosterically and through its influence on receptor expression (Frontiers in Pharmacology, 2018). This is significant in inflammatory pain: arthritis, inflammatory bowel disease, neuroinflammation.

Activation of CB2 reduces the secretion of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and inhibits the migration of immune cells to sites of inflammation. Studies on animal models of rheumatoid arthritis have shown a reduction in swelling and pain after CBD administration (Hammell et al., European Journal of Pain, 2016). However, translation to humans is limited.

Anandamide and the endocannabinoid system

Anandamide (N-arachidonoylethanolamine) was discovered in 1992 by Mechoulam's team. The name comes from the Sanskrit "ananda," meaning "bliss." It is an endogenous cannabinoid produced in response to pain, stress, and physical exertion. Its action is short-lived due to rapid breakdown by FAAH.

CBD prolongs the half-life of anandamide by inhibiting FAAH. This is a key mechanism as it bypasses the need for direct activation of CB1 receptors (which would produce a psychoactive effect like THC). It indirectly enhances natural pain-relieving mechanisms, rather than replacing them. This is a significant difference from opioids, which act through direct stimulation of mu receptors.

Unique observation: CBD is not a "natural opioid." Opioids work externally, pressing classical nociception brakes. CBD modifies the body's self-regulation, giving it more time to calm the pain signal on its own. This difference explains the subtlety of the effect (moderate, not dramatic) and why it does not cause addiction or tolerance in the classical sense.

What studies really show – a review of the evidence

The strongest review of the last decade is the report US from 2017. A team of 16 experts analyzed over 10,000 publications, and the conclusion is: for "cannabinoids" (mainly combinations of CBD/THC), there is strong evidence in chronic pain in adults. For CBD alone without THC, the conclusions are more cautious, and the evidence base is significantly slimmer.

The Cochrane review "Cannabis-based medicines for chronic neuropathic pain" from 2018 included 16 RCTs with 1,750 participants (Mucke et al., Cochrane Database of Systematic Reviews, 2018). Conclusion: cannabinoids provide a small but clinically significant reduction in pain in neuropathy. The Number Needed to Treat (NNT) for a 30% reduction in pain was 11. Safety profile: the Number Needed to Harm (NNH) for adverse effects was 25.

Review BMJ from 2021 (Wang et al., "Medical cannabis or cannabinoids for chronic non-cancer and cancer-related pain") included 32 RCTs and 5,174 patients. Conclusion: moderate quality evidence for small or very small improvements in pain, sleep, and physical functioning. Clinically significant pain reduction ("at least 30%") was more common in the cannabinoid group (29% vs 26% in placebo).

McDonagh 2024 review – current position

The latest systematic review by McDonagh et al. ("Cannabis-Based Products for Chronic Pain", Annals of Internal Medicine, 2022, updated 2024) included 25 RCTs and 3,447 patients. Main conclusions: products with high CBD content and low THC may reduce pain in neuropathy (moderate certainty of evidence), but for musculoskeletal pain, fibromyalgia, and cancer pain, the certainty of evidence is low or very low.

What is particularly important: the authors emphasize that most positive studies use a combination of CBD/THC, not CBD alone. Pure CBD isolate has the least data. The direction of science is "CBD as part of a broader cannabinoid mix," not "CBD alone as a first-line analgesic." This is significant information that marketing often overlooks.

Quality of evidence – what does it mean in practice?

The term "moderate certainty of evidence" in GRADE means that we are moderately confident in the estimate of effect, but further research may change this estimate. "Low certainty" means that the estimate is uncertain and new data will likely change the conclusion. For CBD in neuropathy, we have moderate certainty; for fibromyalgia, low; for nonspecific low back pain, very low.

Practical consequence: CBD may be worth trying in diabetic neuropathy or post-opioid neuralgia, but for nonspecific low back pain, the data do not support this decision. Patients should be aware of the hierarchy of evidence before spending hundreds of zlotys monthly on oils in the hope of "fixing" sciatica or back pain.

The BMJ 2021 review (Wang et al.) on 5174 patients showed that cannabinoids provide a small, clinically significant reduction in pain in chronic non-cancer and cancer pain, with an absolute difference of 3% of patients experiencing at least a 30% improvement. This data confirms a moderate, not dramatic effect (BMJ, 2021).

Neuropathic pain – where the evidence is strongest

Neuropathic pain is an area where cannabinoids have the strongest evidence. According to Cochrane 2018, NNT for a 30% reduction is 11, meaning that for every 11 patients treated, one will achieve clinically significant improvement over placebo. This effect is moderate but comparable to gabapentin in some studies (Finnerup et al., Lancet Neurology, 2015).

Diabetic neuropathy, postherpetic, postoperative, in the context of HIV, chemotherapy – these are typical syndromes where cannabinoids have been tested. Most studies used a combination of CBD/THC (Sativex, nabiximols), but there are also RCTs with pure CBD. The results are consistently moderate: pain reduction of 1-2 points on an 11-point NRS scale, better sleep, reduced opioid consumption.

The guidelines from the European Federation of Neurological Societies (EFNS) from 2010 and the NeuPSIG/IASP update in 2015 do not recommend cannabinoids as first-line treatment for neuropathic pain. First-line treatments are gabapentinoids, TCAs, and SNRIs. Cannabinoids are in the third-line group with a "weak recommendation." This is a realistic position in the therapy hierarchy, far from the marketing of a "miracle drug."

Diabetic neuropathy

The most common cause of neuropathic pain in adults. It affects 16-30% of patients with type 2 diabetes (American Diabetes Association, 2023). In the Wallace et al. study (Journal of Pain, 2015), inhalation of cannabis with a CBD dominance resulted in a pain reduction of 30-40% compared to placebo. The oral form of CBD is less studied, but data indicate a similar direction.

Postherpetic and postoperative neuralgia

Postherpetic neuralgia after varicella-zoster virus infection is a painful syndrome that can last for months. Sativex (1:1 CBD/THC) demonstrated a moderate effect in the analysis of postherpetic neuropathy (Lynch and Campbell, BJCP, 2011). Pure CBD without THC has less data, but mechanistically should work similarly by modulating TRPV1 and 5-HT1A.

Inflammatory and musculoskeletal pain

In inflammatory pain (arthritis, RA, osteoarthritis), the evidence for CBD is promising but mainly from preclinical studies. Frontiers in Pharmacology 2020 summarized animal models where CBD reduced joint swelling by 30-50% and inflammatory markers (TNF-alpha, IL-6) by 40-60%. However, translation to humans is ambiguous and relies on fewer RCTs.

In human studies, the most well-known is the randomized study by Hunter et al. (2018) on 320 patients with knee osteoarthritis. CBD provided a moderate reduction in pain and improvement in function on the WOMAC scale, but the effect was modest (0.8 point difference on a 0-10 scale compared to placebo). Clinically worth considering, but far from dramatic.

Rheumatoid arthritis is an area with the greatest hopes but also the least high-quality data. A small study by Blake et al. (Rheumatology, 2006) with Sativex showed a reduction in resting pain, sleep, and disease activity. Pure CBD without THC has not been tested in a sufficiently large RCT in RA patients.

Osteoarthritis – data from Hunter 2018

The Hunter study on 320 patients is one of the larger RCTs with pure CBD in pain. Dosage: 250 mg/day for 12 weeks. Results: pain reduction of 8% compared to placebo (statistically significant difference, but clinically moderate), improvement in sleep by 14%, no significant difference in morning stiffness. Safety profile: drowsiness in 12%, dry mouth in 9%.

Topical CBD – do they work locally?

CBD creams and ointments are popular in sports marketing. The study by Hammell et al. (European Journal of Pain, 2016) on a rat model of arthritis showed that topical application of CBD reduces joint swelling and inflammatory markers. In humans, the data is limited, but small pilot studies show promising direction in superficial musculoskeletal pain. Topicals do not significantly enter the bloodstream, so they work locally.

Fibromyalgia – mixed results, caution

Fibromyalgia is a syndrome of widespread pain, stiffness, fatigue, and sleep disturbances, affecting 2-4% of the population (van Hecke et al., Pain, 2014). The pathophysiology involves central sensitization and disturbances in descending pain control. Theoretically, CBD should help through 5-HT1A and modulation of central pain processing. However, practice is more nuanced.

A small RCT by van de Donk et al. (Pain, 2019) involving 20 women with fibromyalgia compared cannabis with different CBD/THC profiles. CBD alone without THC did not show a significant advantage over placebo. Only the combination of CBD/THC provided a measurable effect. This study is often cited as "CBD helps with fibromyalgia," but in it, CBD alone failed.

EULAR 2017 guidelines (European League Against Rheumatism) do not recommend cannabinoids as first-line treatment in fibromyalgia. First-line treatments are education, exercise, cognitive-behavioral therapy. Second-line treatments are amitriptyline, duloxetine, pregabalin. Cannabinoids are listed as an experimental option, not standard.

Should you try CBD in fibromyalgia?

From a scientific honesty perspective: the data is mixed. Some patients report subjective improvement in sleep, anxiety, and pain, but these reports may contain a strong placebo effect (known in fibromyalgia to reach 30-40% response). A trial of 8-12 weeks with a dose of 25-50 mg twice daily is rational, but only as part of a comprehensive treatment plan, not instead of it.

Cancer pain – the role of Sativex and CBD alone

In opioid-resistant cancer pain, the strongest evidence is for Sativex (nabiximols), a 1:1 CBD/THC combination in an oral spray. EMA Sativex has been approved in some EU countries as an adjunct in cancer pain. The RCT by Johnson et al. (J Pain Symptom Manage, 2010) showed a pain reduction higher than placebo added to opioids, although the effect was moderate.

CBD alone without THC has significantly weaker data in cancer pain. A study by Good et al. (Journal of Pain and Symptom Management, 2020) involving 144 patients with advanced cancer did not show a significant advantage of CBD over placebo in pain, quality of life, and disease-related symptoms. This is significant because marketing often suggests that CBD "helps with cancer," which is not supported by evidence.

In Poland, Sativex is available only by prescription and often at a cost. The price of about 1500 PLN per month limits accessibility. Patients turning to self-purchased CBD oils as a "cheap alternative to Sativex" receive a product with an incomparable profile. Without THC, there is no effect observed with Sativex in cancer pain.

Adjunct in palliative therapy

In palliative care, CBD is sometimes used to support sleep, anxiety, and nausea caused by chemotherapy. Here, the data is preliminary but clinically used. The study by Bar-Lev Schleider et al. (European Journal of Internal Medicine, 2018) on 2970 oncology patients showed subjective improvement in quality of life in 70% after 6 months of medical cannabis, but this is an observational study without a control group.

What CBD marketing won't tell you

According to the analysis FDA from 2023, over 60% of CBD products sold contained inaccurate health claims, and 30% had actual CBD content differing from the declared by more than 20%. This scale raises questions about transparency in the entire industry. Marketing promises often exceed what studies show.

Common misconceptions: "CBD cures pain," "CBD has no side effects," "natural, therefore safe for everyone," "works for every pain," "better than prescription drugs." Each of these claims is false or greatly exaggerated. CBD does not cure; it alleviates in some syndromes. It has side effects (drowsiness, diarrhea, interactions). It is not safe during pregnancy, for children without medical supervision, or with certain medications.

How to recognize a reputable manufacturer? Publishes certificates of analysis (COA) for each batch. Declares the concentration of CBD and other cannabinoids. Does not promise "cures." Does not quote out-of-context fragments of studies. Provides contact information and answers technical questions. Has a clear return policy. Price appropriate to the product's potency (below 50 PLN for 10 ml of 10% is a warning sign).

From the Bucha editorial office: In our practice, we see that customers asking about CBD for pain often come after 6-12 months of unsuccessful attempts with other supplements. The most common mistake we observe: they start with a dose of 5-10 mg per day and give up after 2 weeks concluding "it doesn’t work." They realistically need doses of 25-50 mg twice a day and 4-8 weeks of regular use to see the effect described in RCT.

Red flags in CBD advertisements

Phrases to avoid: "medical," "therapeutic," "heals," "100% safe," "works faster than drugs," "FDA approved for pain" (FDA has not approved CBD for pain), "clinically proven" without specific studies, "natural alternative to opioids," "thousands of satisfied customers" as the only proof of effectiveness. Each of these phrases should raise caution.

What to really check in a product

CBD concentration on the packaging (mg per milliliter, mg in the whole bottle). Form: isolate, broad spectrum, full spectrum. Presence of THC (broad spectrum: none; full spectrum: up to 0.3%). Carrier oil (MCT is better than hemp for bioavailability). Origin of hemp (EU, USA, Poland). Certificate of analysis with a current date. Terpene profile. Price per milligram of CBD, not per bottle.

Real dosing – how much CBD for pain?

According to the systematic review by McDonagh et al. (2024), most RCTs used doses of 25-50 mg of CBD twice daily, totaling 50-100 mg/day. Lower doses (5-15 mg/day), typical for wellness supplements, have not been adequately tested in chronic pain. Realistically, doses of several dozen milligrams are needed, not single drops.

Practical conversion: one drop of 5% oil is about 2.5 mg CBD, 10% oil is about 5 mg, 15% oil is about 7.5 mg. To obtain 25 mg, you need 10 drops of 5% oil or 5 drops of 10% oil. This is a significant amount daily. A 10 ml bottle of 10% oil contains 1000 mg of CBD, which is enough for about 20 days of dosing 50 mg/day.

Economics matter. 5% concentrations are good for starting, but for chronic pain, 10-15% is more economically sensible. Fewer drops needed, the bottle lasts longer, lower cost per milligram of CBD. 10% oil for 99 PLN gives a price of 0.099 PLN/mg. 5% oil for 76 PLN is 0.152 PLN/mg, which is about 50% more expensive per dose.

Start-low-go-slow protocol

Start with 10 mg of CBD in the evening for 3-7 days. Assess the effect on sleep and pain level in the morning. If tolerance is good, add 10 mg in the morning. After another week, increase the evening dose to 25 mg. Then to 50 mg. The full effect of CBD appears only after 2-4 weeks of regular use, not after the first dose.

When to increase, when to give up

Increase if after 2 weeks at a given dose you see no response. The maximum safely tested in RCTs is about 600 mg/day (Hunter 2018), but for most patients, 50-100 mg is sufficient. Give up if excessive drowsiness, diarrhea, abdominal pain, or drug interactions occur. Also give up after 8-12 weeks without effect, meaning CBD is not the right tool for you.

Time and method of administration

Sublingual drops: hold under the tongue for 60-90 seconds before swallowing. Bioavailability 13-19%, onset of action 15-45 minutes. Capsules: peak after 60-120 minutes, lower bioavailability (6-15%) due to first-pass effect. Cream/ointment: local action, without systemic absorption. Vaping: quick effect (5-10 min), but not recommended for lung diseases and very variable product quality.

Safety and drug interactions

According to the report WHO from 2018, CBD has a good safety profile in humans even at high doses up to 1500 mg/day. The most common side effects are drowsiness (10-25%), diarrhea (8-19%), changes in appetite (5-15%), and fatigue (3-12%). The profile is milder than most pain medications, but CBD is not "side-effect-free."

The most important area of concern is drug interactions. CBD inhibits the enzymes CYP3A4, CYP2C9, and CYP2C19, which metabolize many drugs used in pain therapy. This concerns: warfarin (risk of bleeding), tramadol (risk of serotonin syndrome), methadone, some benzodiazepines, antiepileptics, statins, some antidepressants (FDA Epidiolex prescribing information, 2023).

Pregnant and breastfeeding women should avoid CBD. Safety data is insufficient, and CBD crosses the placenta and into breast milk. FDA issued a warning in 2019 advising against the use of cannabidiol during pregnancy. Children under 18 should not take CBD without pediatric supervision, except for registered indications (Epidiolex).

Hepatotoxicity at high doses

Studies on Epidiolex have shown elevated liver enzymes (ALT, AST) in 13-16% of patients using high doses (10-20 mg/kg/day). For typical pain doses (50-100 mg/day for an adult weighing 70 kg, or about 0.7-1.5 mg/kg), the risk is much lower but not zero. Patients with a history of liver disease should monitor liver enzymes.

Consultation with a doctor – when is it mandatory

Before starting CBD, consult a doctor if: you take anticoagulants, opioids, antiepileptics, antidepressants, statins, or immunosuppressants. Also, if you have liver disease, plan surgery (stop CBD 2 weeks before the procedure), or have a history of addiction. For healthy adults without regular medications, consultation is recommended but not necessary.

Practical patient pathway for chronic pain

CBD is not the first choice in chronic pain. According to the European Pain Federation guidelines 2024, the scheme is: causal treatment (if possible), first-line medications (paracetamol, NSAIDs, gabapentinoids depending on the type of pain), physical therapy, cognitive-behavioral therapy. Only when these methods are insufficient or intolerable are adjuncts, including cannabinoids, considered.

Step 1: establish a diagnosis. Without knowing whether the pain is neuropathic, inflammatory, musculoskeletal, or primary, the choice of therapy is random. A visit to a specialist (neurologist, rheumatologist, pain medicine doctor) is essential. Step 2: exhaust first-line options with your doctor. Step 3: consider CBD as an adjunct, ideally in consultation with a doctor familiar with cannabinoids.

Step 4: choose a product with a COA certificate, broad spectrum, concentration of 10-15% for economical dosing. Step 5: use the start-low-go-slow protocol, aiming for a dose of 25-50 mg twice daily. Step 6: assess the effect after 4 and 8 weeks (VAS pain scale, sleep quality, functioning). Step 7: continue if you see an effect, give up if there is no improvement after 12 weeks.

Pain diary – a mandatory element of the protocol

Without measurement, there is no assessment. Keep a diary: in the morning, rate pain on a scale of 0-10, sleep quality on a scale of 0-5, morning stiffness. After 4 weeks, you will see if CBD provides a real effect or just a placebo lasting the first few days. An average change of 2 points on an 11-point NRS scale is clinically significant.

Combining CBD with other therapies

CBD works best as part of a multimodal therapy. Physical therapy, exercise (yoga, pilates, swimming), cognitive-behavioral therapy, mindfulness, anti-inflammatory diet. CBD alone without these elements provides a modest effect. Combining these tools with a moderate dose of CBD often yields better results than aggressive dosing of the oil alone.

Does formulation matter – isolate vs broad spectrum?

The classic study by Gallily, Yekhtin, and Hanus (Pharmacology & Pharmacy, 2015) showed that full-spectrum extracts provide a stronger analgesic effect than pure CBD isolate at lower doses. The dose-effect curve for the isolate was bell-shaped (effect increases, then decreases), while for full spectrum it was linear. This is significant for patients: broad spectrum may work better.

The mechanism is the entourage effect described by Russo and Mechoulam (British Journal of Pharmacology, 2011). Smaller cannabinoids (CBG, CBN, CBC) plus terpenes (myrcene, beta-caryophyllene, linalool, pinene) act synergistically with CBD. Beta-caryophyllene directly activates CB2 and has its own anti-inflammatory action.

For pain, the practical choice is broad spectrum: it retains synergy, eliminates the risk of THC (important for drivers, athletes tested for doping). Full spectrum is legally OK with THC below 0.3%, but in Poland, availability is limited. Isolate (pure CBD 99%) is applicable only when precise dosing is required without other components (studies, allergies).

What to look for in a COA (Certificate of Analysis)

Current date (max 12 months). CBD and CBG/CBN/CBC concentration. Absence of THC for broad spectrum (below detection limit). Terpene profile (ideally provided). Absence of contaminants: pesticides, heavy metals, solvents, microbiology. Batch number matching the bottle. Accredited independent laboratory (not the manufacturer).

Frequently Asked Questions

Does CBD really work for chronic pain according to clinical studies?

The NASEM 2017 report concluded that there is strong evidence for the effectiveness of cannabinoids (mainly combinations of CBD and THC) in chronic pain in adults. For CBD alone, the Cochrane review from 2018 and BMJ 2021 indicate a moderate reduction in neuropathic pain of about 30% on the NRS scale, but weak evidence for nonspecific lower back pain and ambiguous results in fibromyalgia (BMJ, 2021).

What dose of CBD is effective for chronic pain?

Clinical doses used in randomized studies are usually 25-50 mg of CBD twice daily (50-100 mg/day), administered sublingually (McDonagh et al., systematic review 2024). Lower doses typical for wellness supplements (5-15 mg) have not been tested in chronic pain and likely do not reach the therapeutic threshold. Practically, a 10-15% oil is needed to economically maintain such a dose.

Does CBD help in fibromyalgia?

The evidence is mixed and insufficient. The McDonagh et al. review from 2024 rated the data as low quality. Some small RCTs show moderate pain reduction, while others do not show an advantage over placebo. CBD is not an approved therapy for fibromyalgia in any medical registry (FDA, EMA), and the EULAR 2017 guidelines do not recommend cannabinoids as first-line treatment.

How does CBD work on the TRPV1 and 5-HT1A receptors?

CBD is a partial agonist of the 5-HT1A receptor, which explains its anxiolytic effect and modulation of descending pain. It also activates the TRPV1 channel (vanilloid receptor), involved in nociception, and inhibits the breakdown of anandamide through FAAH (Frontiers in Pharmacology, 2018). These pathways are independent of classical cannabinoid receptors CB1/CB2.

Can CBD interact with pain medications?

Yes. CBD inhibits the enzymes CYP3A4, CYP2C9, and CYP2C19, which may affect the metabolism of opioids (tramadol, codeine), some NSAIDs, gabapentinoids, and warfarin (FDA Epidiolex prescribing information, 2023). Before combining with pain and anticoagulant medications, consultation with a doctor or pharmacist is necessary, especially with drugs that have a narrow therapeutic window.

Does CBD formulation matter – isolate or broad spectrum?

Yes. The study by Gallily et al. (Pharmacology & Pharmacy, 2015) showed that full-spectrum extracts provided better analgesic effects than pure CBD isolate at lower doses, due to the entourage effect (cannabinoids plus terpenes). For chronic pain, broad spectrum is a practical compromise: it retains synergy while eliminating the risk of THC in drug tests.

What has the FDA registered regarding CBD?

The FDA has registered Epidiolex (pure CBD) solely for three indications: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. No pain indication is included in the registration (FDA, 2018). Claims that CBD is an "approved pain medication" are a marketing abuse and can mislead consumers.

Does CBD help with cancer pain?

The evidence for pure CBD is limited. The drug Sativex (combination of CBD + THC, nabiximols) has registration in some EU countries as an adjunct in opioid-resistant cancer pain. Pure CBD without THC in the study by Good et al. (Journal of Pain and Symptom Management, 2020) did not show a significant advantage over placebo in cancer pain. This is a significant limitation of marketing promises.

Summary – what is worth remembering

CBD is not a miracle drug for pain, but it is not an empty trend either. Evidence shows a moderate effect in neuropathic pain (NNT about 11), ambiguous results in fibromyalgia, and a minor role in nonspecific lower back pain. For those with diabetic neuropathy, post-herpetic pain, or systemic inflammatory conditions, CBD is a rational adjunct in the treatment protocol.

The key is real doses (25-50 mg twice a day), broad spectrum formulation, COA certification, patience of 8-12 weeks, and maintaining other treatment elements. Marketing offers "5 drops and the pain will disappear," while science shows "dozens of mg daily for several weeks provides moderate improvement in some patients." These narratives differ significantly.

The worst mistake is treating CBD as a substitute for medical consultation. The best approach is to treat it as a tool in a broader plan known to the attending physician. Then CBD fulfills a role for which there is real evidence: a modest but valuable addition improving sleep, anxiety, and some types of pain in a multimodal therapy protocol.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use CBD for therapeutic purposes, consult a doctor, especially if you are taking pain medications, anticoagulants, antiepileptics, antidepressants, or if you are pregnant or breastfeeding. CBD is not a registered pain medication in Poland or the EU.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Next review: April 26, 2027